Mankind Pharma, India’s fourth largest pharmaceutical business by market share, is going to acquire BSV Group, previously Bharat Serum & Vaccines, from Advent International for roughly ₹13,630 Crore, according to sources familiar with the matter. Mankind will outbid a partnership led by EQT and the Abu Dhabi Investment Authority (ADIA).
Both sides are in the closing stages of discussions, and a formal announcement is likely within the next several days. Once revealed, this will be the largest buyout ever by the company, which was listed a year ago.
The third applicant, a consortium consisting of Warburg Pincus, ChrysCapital, and Mubadala, did not submit a binding offer despite being shortlisted from a larger pool of potential final bidders.
In May, Mankind’s board approved an equity fund raising of ₹7,500 Crore and raised borrowing restrictions to ₹12,500 Crore. As of March 31, 2024, Mankind’s net cash position was ₹3,260 Crore, with no debt. In 2022, the pharma bought Panacea Biotec’s domestic formulation division for ₹1,900 Crore. Dr. Reddy’s also sold it the newborn soap brand Daffy and the asthma treatment brand Combihale.
Mankind has signed an in-licensing arrangement with Novartis for the heart failure treatment Neptaz. Earlier this week, it also signed a non-exclusive patent licensing arrangement with Japanese drugmaker Takeda to commercialise the latter’s Vonoprazan in India.
Vinod G Daftary founded Bharat Serums in Mumbai in 1971. The company develops, manufactures, and markets specialist injectable pharmaceuticals, with a focus on biotech and biological products. The company has a presence in women’s health, assisted reproductive treatment, critical care, and emergency medicine.
At around 11.02 AM, Mankind Pharma was trading 2.99% lower at ₹2,080.30 per piece, against the previous close of ₹2,144.40 on NSE. The counter touched an intraday high and low of ₹2,250, and ₹2,077.05, respectively.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.